StockNews.com Upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) to Strong-Buy

StockNews.com upgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a buy rating to a strong-buy rating in a report published on Friday morning. Other research analysts have also recently issued research reports about the stock. Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They issued […]

Related Keywords

Ourania Tatsis ,Zurcher Kantonalbank Zurich Cantonalbank ,Morgan Stanley ,Sherbrooke Park Advisers ,Telos Capital Management Inc ,Maxim Group ,Wolfe Research ,News Ratings For Vertex Pharmaceuticals Daily ,Analyst Recommendations For Vertex Pharmaceuticals ,Securities Exchange Commission ,Vertex Pharmaceuticals ,Vertex Pharmaceuticals Stock ,Vertex Pharmaceuticals Incorporated ,Hedge Funds Weigh In On Vertex Pharmaceuticals ,Canaccord Genuity Group ,Free Report ,Genuity Group ,Moderate Buy ,Get Free Report ,Exchange Commission ,Chairman Jeffrey ,Park Advisers ,Capital Management ,Kantonalbank Zurich Cantonalbank ,Pharmaceuticals Incorporated ,Vertex Pharmaceuticals Daily ,Nasdaq Vrtx ,Vrtx ,Medical ,92532f10 ,Upgrade ,Stocknews Com ,